What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hypertension (HTN)
- Main trialPhase 1
- “This Phase 1, randomized, double-blind study is designed to evaluate safety, tolerability, PK, and PD effects of AB-110. This study will be conducted in 2 parts: a single ascending dose (SAD; Part A) in healthy participants with an optional cohort of BMI \> 30 kg/m2 and ≤ 35 kg/m2 and multiple ascending dose (MAD; Part B) in participants with hypertension who are otherwise healthy. Sentinel dosing will be applied in the Part A study at each new dose level to ensure participant's safety. The study will provide initial insight into the safety and tolerability of AB-110. In addition to safety,…”In the company’s words, NCT07916961 on ClinicalTrials.gov
Other drugs for Hypertension (HTN)
- BaxdrostatAstraZeneca · Phase 3
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- RalinepagUnited Therapeutics · Phase 3
- OrforglipronEli Lilly · Phase 3
- HCP1803-3Hanmi · Phase 3
Coming up1
- Sep 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Sep 2027 | Study of AB-110 in Healthy and Hypertensive Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026